Leonard Fromer, MD, executive medical director, group practice forum and assistant clinical professor, Department of Family Medicine, University of California, says that proactivity and community collaboration are the best tools to aid transitions of care programs in new care delivery models.
Leonard Fromer, MD, executive medical director, group practice forum and assistant clinical professor, Department of Family Medicine, University of California, says that proactivity and community collaboration are the best tools to aid transitions of care programs in new care delivery models. He explains that the people, assets, and resources found within a community setting can ease the patients’ transition in and out of the hospital, as well to and from primary and specialty care physicians.
Dr Fromer adds that expanding the patient’s care team beyond those who work in the office, making proactive care decisions instead of acting on reactions, and maintaining an active, bidirectional flow of data that follows the patient are “predictors of success.”
“When we look at it that way, when we look at the importance especially in chronic disease of the patient in the community not inside the health system and managing all of those transitions becomes a little more of a lets reach out and make something happen in the right way than wait until it just happens to the patient,” Dr Fromer explains.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More